T.MAN Pharmaceutical PCL, a leader in manufacturing and distributing pharmaceuticals and health products, is ready to trade on the Stock Exchange of Thailand (SET) on 22 October, with a market capitalization at the IPO price of 6,520.06 million baht, using the abbreviation ‘TMAN.’
Ms. Rungtip Charoenvisutthiwong, Assistant Manager, Issuer Group 2, Stock Exchange of Thailand (SET), revealed that the Stock Exchange of Thailand welcomes T.MAN Pharmaceutical PCL to list and start trading on the Stock Exchange of Thailand in the Consumer Products industry group, Personal Care and Medical Supplies category, using the abbreviation ‘TMAN’ on 22 October 2024.
TMAN manufactures and distributes pharmaceuticals and health products under the Company’s own brands of over 200, as well as accepts contract to manufacture and distribute pharmaceuticals and health products under third-party brands. TMAN’s products are divided into four groups: modern drugs, herbal products, dietary supplements, and cosmetics. And other healt
h products with the main brands Propoliz, Iyara, Myda, IBUMAN, Polar and Vita-C as successful brands accepted by consumers.
TMAN has a paid-up registered capital after the IPO of 300 million baht, with a par value of 0.75 baht per share. It offered 102 million common shares to the public for the first time, consisting of 71.43 million new common shares and 30.57 million existing common shares of TKW Capital Limited, offered for sale to persons at the discretion of the underwriter, institutional investors, benefactors of the company, employees of the company and its subsidiaries, and persons related to the company. Between October 10-11 and 15, 2024 at a price of 16.30 baht per share, totaling 1,164.31 million baht in new share capital and a securities value at the IPO price of 6,520.05 million baht, with Kasikorn Securities Public Company Limited as financial advisor and manager of the underwriting and underwriting of the common shares.
Mr. Prapol Thanachotephan, Chief Executive Officer of T.Man Pharmaceuti
cal PCL, revealed that TMAN is committed to creating innovations and effective products to improve the quality of life. With over 50 years of accumulated knowledge and experience, combined with research and development, TMAN is able to develop quality products that meet consumer needs for both disease treatment and prevention, as well as strengthen the brand. TMAN plans to use most of the raised funds to expand and improve production efficiency to support future business growth plans.
TMAN’s major shareholders after the IPO are the Thanachotephan family, which holds a combined 74.5% of the shares. The company has a dividend payment policy of no less than 30% of net profit according to the company’s separate financial statements after corporate income tax and all types of reserves as specified by law and the company’s regulations, taking into account various factors for the benefit of the company and its shareholders.
Source: Thai News Agency